<DOC>
	<DOCNO>NCT01088659</DOCNO>
	<brief_summary>This randomize , single blind study compare antiviral effect Pegasys ( pegylated interferon alfa-2a ) plus placebo versus Pegasys plus tenofovir patient chronic hepatitis D. Patients randomize receive 96 week therapy Pegasys ( 180 microgram sc weekly ) plus either placebo ( orally daily ) tenofovir ( 245mg orally daily ) . Anticipated time study treatment 2+ year , target sample size &lt; 50 .</brief_summary>
	<brief_title>A Study Pegasys ( Peginterferon Alfa 2a ) Alone Combination With Tenofovir Patients With Chronic Hepatitis D .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Hepatitis D , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>adult patient , &gt; /=18 year age chronic hepatitis D positive HBsAg &gt; /=6 month , antiHDV &gt; /=3 month HDVRNA screen negative pregnancy test ; fertile male woman childbearing age use two reliable form contraception throughout study antiviral therapy chronic hepatitis D within previous 6 month previous therapy pegylated interferon alfa treatment conventional interferon alfa &gt; 12 month hepatitis A C , HIV infection decompensated liver disease ( Childs BC ) history evidence medical condition associate chronic liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>